AGENDA

I. Call to order in accordance with New Jersey Open Public Meeting Act

II. Roll Call

III. Review of draft meeting summary for October 19, 2016 meeting

IV. Secretary’s report

V. Old Business
   A. Amerigroup’s response to Miralax® in step therapy for OIC
   B. Naloxone as physician-administered drug from June 2016: indications/diagnosis
   C. Smoking cessation therapy update: Dr. Jill Williams

VI. New Business
   A. Proposed educational newsletter: “Using Naloxone to Prevent Drug Overdose Deaths”
   B. Protocol review:
      1. Smoking cessation products
      2. Addiction treatment drugs

VII. Informational Highlights/Reports
    2. Summary of DURB Action Items
    3. (a) DHS and DHSS Programs Top Drugs Report (by amount paid and by category)
       (b) Physician-administered drugs by amount paid/category
    4. Medication information:
       (a) FDA Approves Bonjesta for Pregnancy-Related Nausea and Vomiting
       (b) Could Common Heartburn Drugs Up Stroke Risk?
       (c) Direct-Acting Antivirals for Hep C might Worsen Liver Cancer
       (d) FDA Announces Stern New Warning Labels for Testosterone Treatments